# Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong

> **NCT03519958** · — · WITHDRAWN · sponsor: **AstraZeneca**

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Plasma-tissue testing

## Key facts

- **NCT ID:** NCT03519958
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-09-30
- **Primary completion:** 2020-11-30
- **Final completion:** 2020-11-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study direction does not longer aligns the sponsor's strategy
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03519958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03519958, "Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03519958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*